BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16000285)

  • 1. Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies.
    Reinhardt MJ; Strunk H; Gerhardt T; Roedel R; Jaeger U; Bucerius J; Sauerbruch T; Biersack HJ; Dumoulin FL
    J Nucl Med; 2005 Jul; 46(7):1158-63. PubMed ID: 16000285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET.
    Sangfelt P; Sundin A; Wanders A; Rasmussen I; Karlson BM; Bergquist A; Rorsman F
    J Hepatol; 2014 Dec; 61(6):1352-7. PubMed ID: 25111173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
    Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
    Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
    Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
    J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
    Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT in the evaluation of adrenal masses.
    Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
    J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of a deep-inspiration breath-hold 18F-FDG PET/CT technique in diagnosing liver, bile duct, and pancreas tumors.
    Nagamachi S; Wakamatsu H; Kiyohara S; Fujita S; Futami S; Arita H; Nishii R; Tamura S; Kawai K
    Nucl Med Commun; 2009 May; 30(5):326-32. PubMed ID: 19282791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hilar cholangiocarcinoma (Klatskin's tumor): up-to-date radiologic diagnosis, intervention and treatment possibilities].
    Goltz JP; Kenn W; Hahn D; Ritter CO
    Dtsch Med Wochenschr; 2009 May; 134(19):985-8. PubMed ID: 19401964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.
    Kluge R; Schmidt F; Caca K; Barthel H; Hesse S; Georgi P; Seese A; Huster D; Berr F
    Hepatology; 2001 May; 33(5):1029-35. PubMed ID: 11343227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the normal adrenal gland with 18F-FDG PET/CT.
    Bagheri B; Maurer AH; Cone L; Doss M; Adler L
    J Nucl Med; 2004 Aug; 45(8):1340-3. PubMed ID: 15299059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP.
    Park MS; Kim TK; Kim KW; Park SW; Lee JK; Kim JS; Lee JH; Kim KA; Kim AY; Kim PN; Lee MG; Ha HK
    Radiology; 2004 Oct; 233(1):234-40. PubMed ID: 15333766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
    Strobel K; Rüdy M; Treyer V; Veit-Haibach P; Burger C; Hany TF
    Nucl Med Commun; 2007 Jul; 28(7):555-9. PubMed ID: 17538397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma.
    Jiang L; Tan H; Panje CM; Yu H; Xiu Y; Shi H
    Clin Nucl Med; 2016 Jan; 41(1):1-7. PubMed ID: 26402131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diabetic foot: initial experience with 18F-FDG PET/CT.
    Keidar Z; Militianu D; Melamed E; Bar-Shalom R; Israel O
    J Nucl Med; 2005 Mar; 46(3):444-9. PubMed ID: 15750157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
    Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
    Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.